| Title |
Profile of omalizumab in the treatment of chronic spontaneous urticaria
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2015
|
| DOI | 10.2147/dddt.s56004 |
| Pubmed ID | |
| Authors |
Moises Labrador-Horrillo, Marta Ferrer |
| Abstract |
Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity receptor FcεRI. It has been largely studied in the field of asthma and is currently approved for the treatment of both adult and pediatric (children; >6-year-old) patients. In addition, in recent, well-controlled clinical trials in patients with CSU resistant to antihistamines, add-on therapy with subcutaneous omalizumab significantly reduced the severity of itching, and the number and size of hives, and increased patients' health-related QoL and the proportion of days free from angioedema compared with placebo, with an excellent tolerance. Thus, omalizumab is an effective and well-tolerated add-on therapy for patients with CSU who are symptomatic despite background therapy with H1 antihistamines. In this review, we cover the following points: epidemiology, pathogenesis, assessment of activity, impact on QoL, and treatment of CSU, and finally, we focus on omalizumab in the treatment of CSU including the pharmacokinetic properties and mechanism of action, and use in pregnant women, nursing infants, and children. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 69 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 14% |
| Researcher | 8 | 12% |
| Student > Master | 6 | 9% |
| Professor > Associate Professor | 5 | 7% |
| Student > Doctoral Student | 4 | 6% |
| Other | 15 | 22% |
| Unknown | 21 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 38% |
| Agricultural and Biological Sciences | 5 | 7% |
| Nursing and Health Professions | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Other | 6 | 9% |
| Unknown | 21 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 September 2015.
All research outputs
#17,438,425
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#1,106
of 2,254 outputs
Outputs of similar age
#165,746
of 276,761 outputs
Outputs of similar age from Drug Design, Development and Therapy
#77
of 148 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,761 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 148 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.